Search research articles
Contact Us
Filters
Showing results (151-160 of 397) with videos related to
Page
of 40
Sort By:
Molecular Cancer Therapeutics
|
August 22, 2013
Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations
Jennifer J Wheler, Apostolia M Tsimberidou, Gerald S Falchook, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery
|
March 7, 2026
Rate of Hearing Loss in Platinum-Naïve Patients Receiving Immune Checkpoint Inhibitors
Kaitlyn A Brooks, Christopher G Gidley, Olivia Grimley, et al.
Investigational New Drugs
|
November 26, 2019
Factors affecting symptom presentation in an early-phase clinical trials clinic patient population
Goldy C George, Tito R Mendoza, Eucharia C Iwuanyanwu, et al.
Cancer Chemotherapy and Pharmacology
|
September 6, 2018
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement
Elena Fountzilas, Elangovan Krishnan, Filip Janku, et al.
Targeted Oncology
|
January 28, 2018
Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor Progression
Marzia Pucci, Pablo Reclusa Asiáin, Elena Duréndez Sáez, et al.
The Oncologist
|
June 10, 2015
The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab
Naifa L Busaidy, Patricia LoRusso, Kristie Lawhorn, et al.
Targeted Oncology
|
March 13, 2026
First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies
Albiruni Razak, Amit Mahipal, Jennifer R Diamond, et al.
Investigational New Drugs
|
March 31, 2015
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer
David S Hong, Filip Janku, Aung Naing, et al.
Thyroid : Official Journal of the American Thyroid Association
|
October 7, 2014
BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer
Gerald S Falchook, Michael Millward, David Hong, et al.
Cancer Chemotherapy and Pharmacology
|
February 11, 2015
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer
Mehmet Asim Bilen, Siqing Fu, Gerald S Falchook, et al.
Page
of 40
Search research articles
Search
Showing results (151-160 of 397) with videos related to
Sort By:
Page
of 40
Molecular Cancer Therapeutics
|
August 22, 2013
Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations
Jennifer J Wheler, Apostolia M Tsimberidou, Gerald S Falchook, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery
|
March 7, 2026
Rate of Hearing Loss in Platinum-Naïve Patients Receiving Immune Checkpoint Inhibitors
Kaitlyn A Brooks, Christopher G Gidley, Olivia Grimley, et al.
Investigational New Drugs
|
November 26, 2019
Factors affecting symptom presentation in an early-phase clinical trials clinic patient population
Goldy C George, Tito R Mendoza, Eucharia C Iwuanyanwu, et al.
Cancer Chemotherapy and Pharmacology
|
September 6, 2018
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement
Elena Fountzilas, Elangovan Krishnan, Filip Janku, et al.
Targeted Oncology
|
January 28, 2018
Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor Progression
Marzia Pucci, Pablo Reclusa Asiáin, Elena Duréndez Sáez, et al.
The Oncologist
|
June 10, 2015
The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab
Naifa L Busaidy, Patricia LoRusso, Kristie Lawhorn, et al.
Targeted Oncology
|
March 13, 2026
First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies
Albiruni Razak, Amit Mahipal, Jennifer R Diamond, et al.
Investigational New Drugs
|
March 31, 2015
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer
David S Hong, Filip Janku, Aung Naing, et al.
Thyroid : Official Journal of the American Thyroid Association
|
October 7, 2014
BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer
Gerald S Falchook, Michael Millward, David Hong, et al.
Cancer Chemotherapy and Pharmacology
|
February 11, 2015
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer
Mehmet Asim Bilen, Siqing Fu, Gerald S Falchook, et al.
Page
of 40